GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO
Adaptimmune Therapeutics plc announced that GlaxoSmithKline plc has exercised its option under a collaboration and license agreement signed in 2014 to exclusively license the right to…
Read More...
Read More...
